Petros Grivas MD, PhD

Dr. Weinberg envisions increasing ctDNA incorporation into adjuvant decision-making, anticipating that Circulate North America results will provide comfort for de-escalating ctDNA-negative patients while escalating ctDNA-positive patients.

Dr. Raez addresses choosing between tumor-informed and tumor-naïve platforms, noting no formal prospective comparison exists.

Dr. Weinberg addresses where evidence is strongest versus where the field risks getting ahead of itself.

Dr. Teplinsky, reflecting on commonalities across tumor types, notes that although the discussion focused on early-stage breast cancer, increasing ctDNA use exists in metastatic disease to identify treatment-emergent mutations guiding therapy selection, representing a different application context.

Dr. Raez discusses IASLC 2025 data, now published in the Journal of Thoracic Oncology, representing important progress for lung cancer's MRD research, which has historically lagged behind gastrointestinal and genitourinary cancers.

Dr. Weinberg addresses practical workflows for ctDNA-positive, imaging-negative patients, noting no current standard of care exists despite NCCN guidelines addressing elevated CEA management.

Dr. Weinberg discusses 2 major observational datasets informing colorectal cancer ctDNA practice.

Dr. Teplinsky discusses the evolving breast cancer surveillance paradigm, noting historical data showing routine imaging surveillance doesn't impact outcomes, though this data predates modern imaging technology.

Dr. Grivas confirms ctDNA integration into multidisciplinary tumor boards is increasing, describing his bladder cancer multidisciplinary clinic involving urology, medical oncology, radiation oncology, and pathology/radiology review focused on localized muscle-invasive bladder cancer.

Dr. Weinberg explains the treatment on molecular recurrence (TOMR) concept, drawing parallels to biochemical relapse monitoring in prostate cancer. In colorectal cancer, patients with positive ctDNA after completing curative-intent surgery and adjuvant chemotherapy will experience radiographic recurrence at a median of approximately 5.5 months, representing a population potentially amenable to curative intervention through escalated imaging to identify oligometastatic disease suitable for metastasectomy, or enrollment in novel drug development trials.

Dr. Teplinsky addresses where ctDNA and MRD testing fit within the patient care continuum, noting that value isn't uniform across disease stages or tumor types. The strongest signal currently exists in the post-treatment surveillance setting, where tumor-informed assays can identify patients at higher recurrence risk before disease becomes visible on imaging.

Dr. John Strickler introduces the program on circulating tumor DNA (ctDNA) and minimal residual disease (MRD) testing across solid tumors, joined by Dr. Eleonora Teplinsky (breast and gynecologic oncology, Valley Health System), Dr. Ben Weinberg (gastrointestinal oncology, Georgetown University), Dr. Petros Grivas (genitourinary oncology, Fred Hutchinson Cancer Center), and Dr. Luis Raez (thoracic oncology, Memorial Healthcare System).

Experts discuss the promising future of ctDNA in bladder cancer treatment, emphasizing its potential to enhance patient outcomes and guide therapy decisions.

Experts discuss the potential of ctDNA in optimizing bladder cancer treatment, questioning overtreatment and exploring personalized therapy approaches.

Experts discuss the operational challenges and evolving use of Cignaera in cancer treatment, highlighting its potential benefits in patient care.

Explore the challenges and advancements in ctDNA-based testing for cancer care, focusing on personalized approaches and sensitivity in diverse tumor types.

Experts discuss the significance of ctDNA testing in cancer treatment, highlighting its role in patient prognosis and treatment decisions.

The Signara assay enhances mutation tracking in urothelial cancer, improving patient outcomes through informed treatment decisions and timely interventions.

Discover the latest insights on ctDNA testing and its impact on relapse risk in muscle-invasive bladder cancer post-surgery.

Experts discuss the evolving treatment landscape for muscle-invasive bladder cancer, highlighting the shift towards perioperative approaches and the role of biomarkers.

Experts discuss the evolving role of ctDNA in adjuvant therapy post-cystectomy, highlighting its prognostic value and implications for treatment decisions.

Recent discussions highlight the significance of ctDNA in adjuvant therapy post-cystectomy, revealing its potential to predict patient outcomes and guide treatment decisions.

Experts discuss the promising results of the Niagara trial, highlighting benefits of cisplatin and durvalumab for unfit patients in cancer treatment.

Experts discuss advancements in muscle invasive bladder cancer, focusing on innovative testing and treatment strategies to enhance patient outcomes.

David H. Aggen, MD, PhD, Petros Grivas, MD, PhD, and Neal Shore, MD, FACS, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in bladder cancer presented during the 2025 ESMO Congress.

Panelists discuss how successful metastatic castration-sensitive prostate cancer (mCSPC) management requires balancing cancer control with quality-of-life preservation, emphasizing the need for better tools to measure patient-reported outcomes, comprehensive survivorship care addressing cardiovascular and bone health, and personalized approaches that help patients understand their prognosis while maintaining their ability to thrive during treatment.

Panelists discuss how quality-of-life considerations are paramount in treatment selection for patients with metastatic castration-sensitive prostate cancer (mCSPC), with data showing that achieving ultralow prostate-specific antigen (PSA) levels correlates with better quality-of-life outcomes and that tolerability profiles, particularly regarding fatigue and drug-drug interactions, significantly impact daily patient experience.

Panelists discuss how managing patients with suboptimal prostate-specific antigen (PSA) response or rising PSA requires careful consideration of PSA kinetics, doubling time, duration of prior response, and imaging findings to determine whether to continue monitoring, add therapy, or transition to castration-resistant treatment approaches.

Panelists discuss how data from the International Registry for Men with Advanced Prostate Cancer (IRONMAN) demonstrates that achieving a prostate-specific antigen (PSA) threshold below 0.2 ng/mL at 6 to 12 months is associated with improved progression-free survival and overall survival regardless of treatment regimen.

Panelists discuss how prostate-specific antigen (PSA) nadir serves as a crucial prognostic marker in metastatic castration-sensitive prostate cancer (mCSPC), with faster drops to lower levels (particularly below 0.2) correlating with better outcomes, whereas imaging frequency should be customized based on clinical status and PSA kinetics.